<DOC>
	<DOCNO>NCT00002568</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug combine chemotherapy surgery may kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy consist paclitaxel cisplatin without surgery treating patient stage III ovarian epithelial cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Surgery Treating Patients With Stage III Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether secondary cytoreductive surgery improve progression-free interval survival patient suboptimally resect stage III ovarian epithelial carcinoma treat paclitaxel/cisplatin . II . Determine morbidity secondary cytoreductive surgery patient . III . Assess prospectively quality life ( QOL ) patient determine whether secondary cytoreductive surgery affect QOL . OUTLINE : Randomized study . Following treatment Regimen A , patient stable objective response randomize Arms I II . Regimen A : 2-Drug Combination Chemotherapy . Paclitaxel ( Bristol-Myers ) , Taxol , NSC-125973 ; Cisplatin , CDDP , NSC-119875 . Arm I : Surgery follow 2-Drug Combination Chemotherapy . Laparotomy resection residual disease ; follow Taxol/CDDP . Arm II : 2-Drug Combination Chemotherapy . Taxol ; CDDP . PROJECTED ACCRUAL : Approximately 470 patient enter 20 month provide 400 evaluable patient .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary ovarian epithelial cancer Stage III disease , i.e . : Greater 1 cm residual intraperitoneal disease follow exploratory laparotomy maximum debulking Laparoscopic resection alone insufficient The following histology eligible : Serous adenocarcinoma Transitional cell carcinoma Mucinous adenocarcinoma Undifferentiated carcinoma Clear cell adenocarcinoma Mixed epithelial carcinoma Adenocarcinoma Endometrioid tumor Adenocarcinoma NOS Malignant Brenner 's tumor No unclassified ovarian cancer ( i.e. , unexplored tumor think ovarian origin tumor verify arise ovarian stroma ) No borderline ( grade 0 ) `` probably malignant '' carcinoma Measurable disease prefer Patients eligible protocol also eligible protocol GOG136 PATIENT CHARACTERISTICS : Age : Any age Performance status : GOG 02 Hematopoietic : WBC least 3,000/mm3 Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin 1.5 time normal ALT , AST , GGT 3 time normal Alkaline phosphatase 3 time normal LDH 3 time normal Renal : Creatinine 2.0 mg/dL Cardiovascular : No history congestive heart failure No myocardial infarction within 6 month No unstable angina Other : No septicemia severe infection No acute hepatitis No severe gastrointestinal bleeding No second malignancy within 5 year except nonmelanomatous skin cancer Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytotoxic chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics No 6 week since stag surgery</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>Brenner tumor</keyword>
</DOC>